Aurora Cannabis Inc.

TSX:ACB.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$6.31 +0.48%

+$0.02 today

Market cap
$414.85M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $3.77High $9.33

Volume 0.32M

Average 0.42M

ACB.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aurora Cannabis Inc.TSX: ACB.TO

Research & Development · Q4 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q4 FY2026 research & development of CA$986K rose 25.6% year over year, behind the +31.9% change in trailing-twelve-month research & development. Sequentially, it fell 43.5% from the prior quarter. Over 3 fiscal years it compounded at -15.1% a year.

Context

  • Research & development amounted to 1.3% of revenue in FY2026, up 0.2 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +25.6% toward the trailing-twelve-month pace of +31.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$986K-43.5% QoQ
Last fiscal yearMar 2026
CA$4.02M+9.4% YoY
LTMMar 2026
CA$4.85M+31.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+9.4%——
3-year CAGR-15.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2026
4.02M CAD
Year-over-year change
+9.4%
4-year CAGR
-21.1%

Research & Development vs competitors

How ACB.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.9% is the 2nd highest of 6, against a peer median of -48.4%.
  • Research & development amounts to 1.5% of revenue for ACB.TO, versus a peer median of 0.2%.
ACB.TO Competitors
Research & Development for ACB.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$10.02M CAD+9.4%—3.7%
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$4.85M CAD+31.9%-15.1%1.5%
EDT.TOSpectral Medical Inc.LTM Mar 2026CA$1.84M CAD-59.9%—66.7%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$267K CAD+62.8%—0.2%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$205.18K USD-48.4%-58.4%0.4%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$0 CAD——0.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$0 USD-100.0%-39.8%0.0%
TSND.TOTerrAscend Corp.LTM Mar 2026$0 USD——0.0%
Peer median (excluding ACB.TO) —-48.4%-49.1%0.2%

Competitors are the stored peer set for ACB.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M233.29M270.28M343.29M320.59M
Cost of Revenue200.11M297.65M138.82M155.69M303.89M
Gross Profit21.23M(64.36M)131.46M187.61M16.7M
Gross Margin9.6%-27.6%48.6%54.6%5.2%
Research & Development10.39M6.56M3.57M3.68M4.02M
Selling, General & Admin188.99M183.4M156.88M166.47M173.5M
Operating Expenses252.67M189.96M177.91M182.66M179.5M
Depreciation & Amortization93.66M43.57M33.07M22.55M14.19M
EBITDA(1.55B)(210.74M)(12.34M)51.35M(162.79M)
EBITDA Margin-702.4%-90.3%-4.6%15.0%-50.8%
Operating Income(231.45M)(254.32M)(46.45M)4.95M(162.79M)
Operating Margin-104.6%-109.0%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.85M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(41.1M)(13.15M)15.43M106.27M
Income Before Tax(1.72B)(295.42M)(59.6M)20.38M(56.52M)
Pre-Tax Margin-777.1%-126.6%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)(20.32M)(554K)4.62M2.1M
Net Income(1.72B)(265.33M)(69.33M)1.59M(121.76M)
Net Margin-776.0%-113.7%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

TSX:ACB.TO

Intrinsic Alpha fair value

Locked

Current Price

$6.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.